Esophageal Clinical Trials in Beijing, Beijing Municipality
42 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 42 trials
Recruiting
Phase 1Phase 2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Gastric CancerEndometrial CancerHepatocellular Carcinoma+5 more
Seagen, a wholly owned subsidiary of Pfizer714 enrolled61 locationsNCT05208762
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb949 enrolled48 locationsNCT04895709
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled160 locationsNCT07221149
Recruiting
Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting
Not Applicable
Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
Esophageal CancerGastric CancerHypoxemia+1 more
Zhejiang University410 enrolled5 locationsNCT07175155
Recruiting
Phase 1
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+5 more
I-Mab Biopharma US Limited330 enrolled21 locationsNCT04900818
Recruiting
Phase 1Phase 2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Colorectal, CancerEsophageal CancerOvarian Cancer+12 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
Phase 3
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Akeso760 enrolled6 locationsNCT07023315
Recruiting
Phase 2
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Colorectal, CancerEsophageal CancerGastric Cancer
Sichuan Baili Pharmaceutical Co., Ltd.376 enrolled1 locationNCT06008054
Recruiting
Phase 1
APG-2449 in Patients With Advanced Solid Tumors
Esophageal CancerOvarian CancerNon-small Cell Lung Cancer+2 more
Ascentage Pharma Group Inc.165 enrolled9 locationsNCT03917043
Recruiting
Phase 1
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
Gastroesophageal Junction AdenocarcinomaAdvanced or Metastatic Gastric Cancer
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.80 enrolled1 locationNCT06773312
Recruiting
Not Applicable
Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
Esophageal CancerGastric CancerPrecision Screening+2 more
Peking University Cancer Hospital & Institute21,000 enrolled1 locationNCT06306755
Recruiting
Phase 1Phase 2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Esophageal CancerStomach CancerStomach Cancer Recurrent+4 more
Essen Biotech75 enrolled1 locationNCT06532799
Recruiting
Phase 2
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT06498752
Recruiting
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Breast CancerLiver CancerColorectal, Cancer+10 more
Beijing Friendship Hospital2,700 enrolled4 locationsNCT06363123
Recruiting
Phase 2Phase 3
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.90 enrolled12 locationsNCT06221748
Recruiting
Phase 3
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd486 enrolled1 locationNCT06177041
Recruiting
Phase 2
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.90 enrolled11 locationsNCT06155383